On June 13, 2024, the US Supreme Court handed the Biden Administration, reproductive health advocates, and the US Food and Drug Administration (FDA) an important win. The Court鈥檚 unanimous opinion allowed mifepristone, one of 2 drugs approved by the FDA in a regimen for medication abortion, to remain widely available in the United States.1 This case was one of the most anticipated of this term, particularly as roughly 63% of abortions are now facilitated with the use of mifepristone.2 In its ruling, the Court let stand scientific decisions of the FDA to expand access to mifepristone without the reimposition of onerous requirements that had been in place prior to 2016.